Weiss Ratings Reaffirms Sell (E+) Rating for 180 Life Sciences (NASDAQ:ATNF)

Weiss Ratings reiterated their sell (e+) rating on shares of 180 Life Sciences (NASDAQ:ATNF) in a report issued on Wednesday morning,Weiss Ratings reports.

180 Life Sciences Stock Performance

Shares of ATNF opened at $1.25 on Wednesday. The company’s 50-day moving average price is $1.63 and its 200 day moving average price is $2.11. 180 Life Sciences has a 12-month low of $1.16 and a 12-month high of $17.75.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in 180 Life Sciences stock. Anson Funds Management LP acquired a new stake in 180 Life Sciences Corp. (NASDAQ:ATNF) during the fourth quarter, according to its most recent filing with the SEC. The firm acquired 225,271 shares of the company’s stock, valued at approximately $410,000. Anson Funds Management LP owned about 7.08% of 180 Life Sciences at the end of the most recent reporting period. Hedge funds and other institutional investors own 4.07% of the company’s stock.

180 Life Sciences Company Profile

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor.